Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

Completed · Phase 4

Conditions studied: Erosive Esophagitis

In brief

The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.

Key facts

Study ID

NCT00693225

Run by

Yvonne Romero

People needed

91

Starts

2008-01-01

Expected to finish

2010-12-01

Last updated by the study team

2012-09-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who have either moderate to severe erosive esophagitis (Los Angeles grade C or D)
• Subjects with esophagitis despite use of a non-omeprazole Proton Pump Inhibitor (PPI)(s) or histamine receptor antagonist (HRA) were invited to participate without a wash-out period.
• Subjects able to return to Mayo Clinic Rochester for follow up endoscopy 8 weeks after start of study.
• Female subjects are eligible if they are not pregnant or lactating and one of the following criteria is met:
• Surgically sterile (by means of hysterectomy or bilateral tubal ligation).
• At least one year postmenopausal (no menses for greater than or equal to 12 months).
• Subject is using a highly effective method of contraception, if of childbearing potential and has a negative urine human chorionic gonadotropin beta subunit (B-HCG) pregnancy test during screening, and prior to trial drug administration.

You may not qualify if…

• Subjects already on or failed omeprazole in past, or intolerant of PPI therapy
• Subjects who are using clopidogrel (Plavix)
• Subjects with one or more of the following diagnoses:
• Neoplasm of the esophagus or stomach
• Previous upper gastrointestinal surgery (esophagectomy, Heller myotomy, hiatal hernial repair)
• Diabetic gastroparesis
• Esophageal motility disorder: Achalasia or scleroderma
• Zollinger-Ellison syndrome
• Infection with human immunodeficiency virus (HIV)
• Bleeding diathesis
• History of gastric or small bowel obstruction
• Inability to read due to blindness, cognitive dysfunction, English language illiteracy
• Disorders which predispose to unreliable responses such as Schizophrenia, Alzheimer's disease or significant memory loss
• Pregnant and lactating females will be excluded as PPIs are not thought safe for the fetus (Pregnancy Category C).
• Children younger than 18 years of age will be excluded as their compliance might be dictated by others, such as their parents, and their results would not be generalizable to the adult population. Other vulnerable populations, such as those with diminished mental acuity, will be excluded for the same reason.
• Residence outside of the US (due to difficulties with overseas postal service) or in prison.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.